DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Overview
- Therapeutics Development
- Pipeline Products for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview
- Pipeline Products for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics under Development by Companies
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Products under Development by Companies
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Products under Investigation by Universities/Institutes
- Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development
- Absynth Biologics Limited
- Actelion Ltd
- Adenium Biotech ApS
- AIMM Therapeutics B.V.
- Alchemia Limited
- Allergan Plc
- AlphaMab Co., Ltd
- Alvogen Korea Co., Ltd.
- AmpliPhi Biosciences Corporation
- AnGes MG, Inc.
- Aphios Corporation
- Arsanis Biosciences GmbH
- AstraZeneca Plc
- Aurigene Discovery Technologies Li
- Bavarian Nordic A/S
- Bharat Biotech International Limited
- BioDiem Ltd
- C3 Jian, Inc
- Cellceutix Corporation
- Cempra, Inc.
- ContraFect Corporation
- CrystalGenomics, Inc.
- CSA Biotechnologies LLC
- Debiopharm International SA
- DesignMedix, Inc.
- Destiny Pharma Limited
- Emergent BioSolutions Inc.
- Ensol Biosciences Inc.
- Excelimmune, Inc.
- Galapagos NV
- GangaGen Inc.
- Gero Corp
- Helix BioMedix, Inc.
- Hsiri Therapeutics, LLC
- Ildong Pharmaceutical Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/7hbtt8/methicillinresist
